Randle L E, Sathish J G, Kitteringham N R, Macdonald I, Williams D P, Park B K
Department of Pharmacology and Therapeutics, The University of Liverpool, Liverpool, UK.
Br J Pharmacol. 2008 Feb;153(4):820-30. doi: 10.1038/sj.bjp.0707620. Epub 2007 Dec 10.
Paracetamol, a major cause of acute liver failure (ALF) represents a significant clinical problem. Adrenoceptor stimulation or antagonism can modulate chemical-induced hepatotoxicity. We investigated the role of endogenous catecholamines and alpha(1)-adrenoceptors in the development of paracetamol- induced hepatotoxicity.
Paracetamol (3.5 mmol kg(-1)) was administered to male CD-1 mice, with and without alpha(1)-adrenoceptor antagonists (prazosin, doxazosin, terazosin and tamsulosin; 35.7 micromol kg(-1)). Serum transaminases and hepatic glutathione (GSH) levels were assessed as markers of hepatic damage. Paracetamol bioactivation was assessed by covalent binding, hepatic and urinary conjugate formation and uridine glucuronosyltransferase activity. Plasma catecholamines levels and hepatic congestion were also analysed.
Plasma catecholamine levels were significantly elevated 5 h post paracetamol administration. Prazosin prevented hepatotoxicity when administered 1 h before a toxic paracetamol insult and importantly, when administered up to 1 h post paracetamol injection. Prazosin had no effect on paracetamol-induced depletion of hepatic GSH, paracetamol bioactivation or paracetamol-induced transcription of defence genes. Paracetamol toxicity is associated with marked accumulation of erythrocytes within hepatic sinusoids and prazosin completely prevented this accumulation.
Paracetamol-induced hepatocellular damage is associated with increased circulating catecholamines. alpha(1)-Adrenoceptor antagonists conferred complete protection from paracetamol -induced hepatotoxicity. Protection was associated with absence of hepatic erythrocyte accumulation. Increased catecholamine levels may contribute to the pathophysiology of paracetamol-induced hepatotoxicity by compromising hepatic perfusion. Protection against paracetamol toxicity by alpha(1) antagonists in mice has implications for therapeutic management of patients presenting with paracetamol overdose and ALF.
对乙酰氨基酚是急性肝衰竭(ALF)的主要病因,这是一个重大的临床问题。肾上腺素能受体激动或拮抗可调节化学物质诱导的肝毒性。我们研究了内源性儿茶酚胺和α1肾上腺素能受体在对乙酰氨基酚诱导的肝毒性发展中的作用。
给雄性CD-1小鼠给予对乙酰氨基酚(3.5 mmol kg-1),分别给予和不给予α1肾上腺素能受体拮抗剂(哌唑嗪、多沙唑嗪、特拉唑嗪和坦索罗辛;35.7 micromol kg-1)。评估血清转氨酶和肝谷胱甘肽(GSH)水平作为肝损伤的标志物。通过共价结合、肝和尿中结合物形成以及尿苷葡糖醛酸基转移酶活性评估对乙酰氨基酚的生物活化。还分析了血浆儿茶酚胺水平和肝充血情况。
对乙酰氨基酚给药后5小时,血浆儿茶酚胺水平显著升高。在给予毒性剂量的对乙酰氨基酚前1小时给予哌唑嗪可预防肝毒性,重要的是,在对乙酰氨基酚注射后长达1小时给予哌唑嗪也可预防。哌唑嗪对对乙酰氨基酚诱导的肝GSH耗竭、对乙酰氨基酚生物活化或对乙酰氨基酚诱导的防御基因转录没有影响。对乙酰氨基酚毒性与肝血窦内红细胞明显积聚有关,而哌唑嗪完全阻止了这种积聚。
对乙酰氨基酚诱导的肝细胞损伤与循环儿茶酚胺增加有关。α1肾上腺素能受体拮抗剂可完全保护免受对乙酰氨基酚诱导的肝毒性。保护作用与肝内无红细胞积聚有关。儿茶酚胺水平升高可能通过损害肝灌注而导致对乙酰氨基酚诱导的肝毒性的病理生理学改变。小鼠中α1拮抗剂对乙酰氨基酚毒性的保护作用对乙酰氨基酚过量和急性肝衰竭患者的治疗管理具有启示意义。